Overview

Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Recurrent or Progressed Following Treatment

Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT) glioma with FGFR-TACC gene fusion that has come back (recurrent) or that is growing, spreading, or getting worse (progressive). Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals cancer cells to multiply. This may help keep cancer cells from growing and may kill them. Giving erdafitinib may help to slow the growth of or to shrink tumor cells in patients with recurrent or progressive IDH-wild type glioma with FGFR-TACC gene fusion.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)